Epidiolex /mL
Phase 1Small molecule
Jazz PharmaceuticalsEpidiolex /mL is one of 37 small molecule programs targeting Tuberous Sclerosis. It is currently in Phase 1.
2
Indications
5
Total Trials
3
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
41 competitors in Status Epilepticus
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Ketalar
AAultman Health Foundation
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Epidiolex
Jazz PharmaceuticalsApproved
Depakote
AbbViePhase 3
Vimpat
UCBPhase 3
Actemra
RochePhase 3
Ativan
BBausch Health Americas, Inc.
Phase 3
Luminal
BBiomed Industries, Inc.
Phase 3
Fintepla
IImmedica Pharma AB
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Dental Pain1 trial
CBD for Dental Pain
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1/2·NCT04642404·64 enrolled
Buprenorphine1 trial
Children1 trial
Status Epilepticus1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Epidiolex /mL. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company